Selective removal of aging cells opens new possibilities for treating age-related diseases

A research team, led by Professor Ja Hyoung Ryu from the Department of Chemistry at UNIST, in collaboration with Professor Hyewon Chung from Konkuk University, has achieved a significant breakthrough in the treatment of age-related diseases. Their cutting-edge technology offers a promising new approach by selectively removing aging cells, without harming normal healthy cells. This groundbreaking development is poised to redefine the future of healthcare and usher in a new era of targeted therapeutic interventions.
Aging cells, known as senescent cells, contribute to various inflammatory conditions and age-related ailments as humans age. To address this issue, the research team focused on developing a technology that could precisely target and eliminate aging cells, while sparing normal healthy cells.
In their study, the team designed organic molecules that selectively target receptors overexpressed in the membranes of aging cells. By leveraging the higher levels of reactive oxygen species (ROS) found in aging cells, these molecules promote the formation of disulfide bonds and create oligomers that bind together.
Through self-assembly of these oligomers, the researchers successfully created artificial proteins with a stable α-helix secondary structure. These protein-like nanoassemblies exhibited strong binding affinity to the mitochondrial membranes of aging cells, leading to membrane disruption and subsequent cell self-destruction.
“The selective removal of aging cells by targeting the mitochondria and inducing dysfunction has been successfully demonstrated in our experiments,” stated Professor Ryu. “This approach represents a new paradigm for treating age-related diseases.”
This innovative technology offers several advantages, including minimal toxicity concerns and a wide therapeutic window by specifically targeting organelles within cells. It opens up exciting possibilities for designing preclinical and clinical trials in the future.
Supported by the National Research Foundation of Korea (NRF) and the Ministry of Science and ICT (MSIT), this groundbreaking research has been published in the online version of the Journal of the American Chemical Society (JACS) on September 4, 2023.

Read more →

Should fathers be screened for postpartum depression? Pilot study

Dads can suffer from postpartum depression, and a new pilot study at the University of Illinois Chicago suggests they can and should be screened for the condition. Given the intertwined effects of mothers’ and fathers’ physical and mental health, addressing the health of fathers may be a powerful untapped tool in improving the nation’s ongoing maternal health crisis.
The researchers got mothers’ permission to interview and screen 24 dads, 30% of whom screened positive for postpartum depression on the same tool that is commonly used to screen moms. Lead author Dr. Sam Wainwright said this points to the importance of asking new dads how they’re doing.
“A lot of dads are stressed. They’re scared. They’re struggling with balancing work and parental and partner responsibilities,” he said. “Men are often not doing well, but no one is asking them about it.”
Talking to new dads about their mental health takes on additional importance when considering how it can impact their partners’ health.
“A woman at risk for postpartum depression is much more likely to get postpartum depression if she has a depressed partner,” said Wainwright, assistant professor of internal medicine and pediatrics.
Other studies have estimated that 8% to 13% of new fathers have postpartum depression. Wainwright suspects this study’s rate was higher because nearly 90% of the participants identified as being from a racial or ethnic group that faces issues of structural racism and social determinants that can worsen mental health.
The study, published in the journal BMC Pregnancy and Childbirth, was conducted at UI Health’s Two-Generation Clinic. Opened in 2020, the clinic grew out of the understanding that new mothers, especially low-resource mothers of color who are taking on parenthood alongside a host of structural challenges often do not prioritize their own health care. However, they are often very diligent in bringing their children to the doctor, Wainwright explained. The Two-Generation Clinic capitalizes on children’s visits by offering moms primary care at the same time.

Read more →

Study raises concerns over powdered infant formula preparation machines

A study by Swansea University academics in the UK into powdered infant formula preparation safety has revealed that 85% of the 74 infant formula preparation machines tested by parents in UK homes did not appear to produce water that would be hot enough to kill all harmful bacteria in infant formula, and this could pose a serious risk to infant health.
This was compared to 69 parents in the study who used a kettle to heat the water used to prepare infant formula, where 22% reported water temperatures that were not hot enough to kill all harmful bacteria.
Almost three quarters of infants in the UK are fed infant formula in the first six weeks of life and this rises to 88% by six months of age.
Formula-fed infants have a higher risk of gastrointestinal infections compared to breastfed infants1 which can be attributed, in part, to bacterial contamination from: the powdered infant formula itself (which cannot be made sterile), the equipment used for feeding, and also preparing infant formula with unclean hands. To help reduce the risk of such infections, the NHS has adopted the World Health Organization (WHO) recommendation that water used to make infant formula should be boiled and cooled, so that it is at a temperature of at least 70oC to eliminate bacteria.
The study, which explored the safety of infant formula preparation practices compared to NHS guidelines, used community science methods and involved parents of infants aged 12 months or under. Around half of the 143 parents (74 people) used infant formula preparation machines while the remaining 69 parents used kettles to boil the water for infant formula preparation.
Dr Aimee Grant, Senior Lecturer in Public Health, who led the study stated:
“I was concerned to find that of the 74 infant formula preparation machines tested by parents, 85% appeared to fail to reach a temperature of at least 70oC, which the NHS say is needed to kill all bacteria that can live in powdered infant formula. If any parents are worried, I’d advise them to buy a food thermometer and test the temperature of just the hot water that comes out of their machine (but not to use this tested water in a feed, due to potential contamination); if it’s below 70 degrees, do not use the machine to prepare infant formula and contact the machine manufacturer.”
Jonie Cooper, a parent who took part in the study, said: “When I first tested my prep machine, using the setting for a 4-ounce bottle of formula, I got a temperature of 52oC. When I saw this I was shocked because I trusted the machine to follow the NHS guidelines on the temperature of the water, because it was specifically designed for babies. I advise parents using a prep machine to check the temperature of the water.”

Read more →

Wastewater detects signs of antimicrobial resistance in aged care facilities

A new study published today, analysing wastewater samples from several aged care and retirement homes in Adelaide, has uncovered worrying signs of antimicrobial resistance (AMR) in at least one facility.
High levels of bacterial resistance against three common antibiotics — ceftazidime, cefepime and ciprofloxacin — were identified in one aged care residential home. A second facility recorded above average levels of antimicrobial resistance to gentamicin, putting residents’ health at risk.
The listed antibiotics are used to treat a variety of bacterial infections, including pneumonia, gynaecological, urinary and respiratory tract infections, and those affecting bones and joints.
University of South Australia microbiologist, Associate Professor Rietie Venter, who led the study, says AMR is a concerning trend in aged care facilities.
“Antimicrobial resistance is projected to lead to 300 million deaths worldwide by 2060, and aged care residents are among the most vulnerable due to frequent, inappropriate use of medicines,” Assoc Prof Venter says.
Although the wastewater study was confined to three sites and 300 residents, the findings suggest a much wider problem, and are a clear warning to aged care facilities to implement stricter policies when it comes to medication use.
“As well as increasing death rates, AMR can lengthen illness recovery times, especially for immunocompromised people who make up a high proportion of people in aged care homes.”
Accurately monitoring the misuse and overuse of antibiotics in residential aged care homes is challenging, hence the use of wastewater-based surveillance, believed to be a first for this sector.
According to the Australian Commission on Safety and Quality in Health Care, general rates of antimicrobial resistance have not significantly changed in the past two years. However, there are exceptions to this, including increasing resistance to ceftriaxone and fluoroquinolones. Both antibiotics are widely used in aged care settings, despite clinical guidelines recommending them as ‘last resort’ drugs.
“The results of this study highlight the need for ongoing surveillance of residential aged care facilities when it comes to medication use,” Assoc Prof Venter says. “Given our ageing population, there is a crucial need to regularly monitor these facilities and mitigate the threat of AMR.”

Read more →

Women living in more walkable neighborhoods have lower rates of obesity-related cancers

Residing in a more walkable neighborhood protects against the risk of overall obesity-related cancers in women, specifically postmenopausal breast cancer, but also ovarian cancer, endometrial cancer, and multiple myeloma, according to a new study by Columbia University Mailman School of Public Health and NYU Grossman School of Medicine. Obesity has been linked to increased risk for 13 types of cancer in women, and physical activity, independent of body size, lowers risk for some of these cancers. Neighborhood walkability is a set of urban design features that promotes pedestrian activity, supports overall physical activity and is associated with lower body mass index. However, until now long-term studies of neighborhood walkability and risk for obesity-related cancer were limited. The findings are published in the journal Environmental Health Perspectives.
Women who resided in neighborhoods with higher walkability levels, as measured by average destination accessibility and population density over approximately 24 years of follow-up, had lower risk of obesity-related cancers, particularly postmenopausal breast cancer. However, moderate protective associations were also found for endometrial cancer, ovarian cancer, and multiple myeloma. Women in who had lived in areas with the highest levels of neighborhood walkability (the top 25 percent of walkability) had a 26 percent lower risk of obesity-related cancers compared to those who lived in neighborhoods in the lowest 25th percent of walkability.
“These results contribute to the growing evidence of how urban design affects the health and wellbeing in aging populations,” said Andrew Rundle, DrPH, professor of epidemiology at Columbia Mailman School. Individual-level interventions to increase physical activity and reduce obesity are costly and often have only short-term effects, according to Rundle and colleagues. “However, urban design can create a context that promotes walking, increases overall physical activity, and reduce car-dependency, which could lead to subsequent improvements in preventing diseases attributed to unhealthy weight,” Rundle observed.
“We further observed that the association between high neighborhood walkability and lower risk of overall obesity-related cancers was stronger for women living in neighborhoods with higher levels of poverty” said Sandra India-Aldana, Ph.D., Icahn School of Medicine at Mount Sinai, and lead author. “These findings suggest that neighborhood social and economic environments are also relevant to risk of developing obesity-related cancers.”
The researchers studied 14,274 women between the ages of 34 and 65 and recruited at a mammography screening center in NYC between 1985 and 1991 and followed them over nearly three decades. They measured neighborhood walkability in the participant’s residential Census-tract throughout follow-up and assessed the association between neighborhood walkability and risk of overall and site-specific obesity-related cancers including postmenopausal breast cancer, ovarian cancer, endometrial cancer, and multiple myeloma. Of the total number of women studied, 18% had a first obesity-related cancer by the end of 2016.The most common cancer was postmenopausal breast cancer at 53%, followed by colorectal cancer at 14%, and endometrial cancer at 12%.
“Our study is unique in that the long-term follow-up allowed us to study effects of walkability with potential long latency periods of cancer and we were able to measure neighborhood walkability as the participants moved residences around the country during follow-up” said co-author Yu Chen Ph.D., NYU Grossman School of Medicine.
Other co-authors are Tess Clendenen, Yelena Afanasyeva, Karen Koenig, and Anne Zeleniuch-Jacquotte, NYU Grossman School of Medicine; Mengling Liu and Lorna Thorpe, NYU Grossman School of Medicine and NYU Langone Health; James W. Quinn, Columbia Mailman School of Public Health; and Kathryn Neckerman, Columbia University Population Research Center.
The study was supported by U.S. NIH grants UM1CA182934-01A1, UM1CA182934-05-S1, P30CA016087, P30ES000260, 1R01AG049970, and 3R01AG049970.

Read more →

Scientists develop 3D printing method that shows promise for repairing brain injuries

Researchers have produced an engineered tissue representing a simplified cerebral cortex by 3D printing human stem cells. When implanted into mouse brain slices, the structures became integrated with the host tissue.
The breakthrough technique developed by University of Oxford researchers could one day provide tailored repairs for those who suffer brain injuries. The researchers demonstrated for the first time that neural cells can be 3D printed to mimic the architecture of the cerebral cortex. The results have been published today in the journal Nature Communications.
Brain injuries, including those caused by trauma, stroke and surgery for brain tumours, typically result in significant damage to the cerebral cortex (the outer layer of the human brain), leading to difficulties in cognition, movement and communication. For example, each year, around 70 million people globally suffer from traumatic brain injury (TBI), with 5 million of these cases being severe or fatal. Currently, there are no effective treatments for severe brain injuries, leading to serious impacts on quality of life.
Tissue regenerative therapies, especially those in which patients are given implants derived from their own stem cells, could be a promising route to treat brain injuries in the future. Up to now, however, there has been no method to ensure that implanted stem cells mimic the architecture of the brain.
In this new study, the University of Oxford researchers fabricated a two-layered brain tissue by 3D printing human neural stem cells. When implanted into mouse brain slices, the cells showed convincing structural and functional integration with the host tissue.
Lead author Dr Yongcheng Jin (Department of Chemistry, University of Oxford) said: ‘This advance marks a significant step towards the fabrication of materials with the full structure and function of natural brain tissues. The work will provide a unique opportunity to explore the workings of the human cortex and, in the long term, it will offer hope to individuals who sustain brain injuries.’
The cortical structure was made from human induced pluripotent stem cells (hiPSCs), which have the potential to produce the cell types found in most human tissues. A key advantage of using hiPSCs for tissue repair is that they can be easily derived from cells harvested from patients themselves, and therefore would not trigger an immune response.

Read more →

Tracking the bacteria behind life-threatening sepsis in premature babies

Premature babies in neonatal care units are extremely vulnerable, and susceptible to life-threatening infections. To help keep these babies safe the risk of infection needs to be kept as low as possible.
A particular problem is late onset sepsis that starts from three days after birth, when bacteria get into the blood and grow. This can be very dangerous and babies with late onset sepsis end up staying in hospital longer, need more treatment with antibiotics and can be left with life-long effects on their health.
Bacteria from the Staphylococcus family are the most common causes of late onset sepsis. Most members of this large group of bacteria are harmless; they are normal colonisers of our skin, which can even protect us from harmful microbes. However, some strains, when they end up in the wrong place and get inside the body, can cause major problems, particularly for immunocompromised individuals like neonatal babies.
Staphylococcus capitis is an example of this. This is a species which is usually content living on our scalp, face and neck; capitis means “of the head’ in Latin. Some strains of S. capitis are however associated with late onset sepsis. One particular strain, known as NRCS-A, has been identified as causing serious infections in neonates around the world.
Scientists think this strain first emerged in the 1960s and spread globally throughout the 1980s as it evolved resistance to the commonly used antibiotic vancomycin. Strains circulating now show resistance to multiple antibiotics and a reduced susceptibility to antiseptics that we use to sterilise the skin of babies. This makes the bacteria harder to treat and control, but exactly why this NRCS-A strain has become so globally successful has remained a mystery.
To try and understand what makes this strain able to spread around the world and to develop better ways to keep it under control, Professor Mark Webber and his team from the Quadram Institute and University of East Anglia analysed the genomes of hundreds of S. capitis isolates. They worked with two Neonatal Intensive Care Units (NICUs), one in the UK and one in Germany, obtaining samples of S. capitis from the skin and gut of neonatal babies, with and without late onset sepsis.
Their results, published in the journal Microbial Genomics, found that the NRCS-A strain was commonly carried on the skin and in the gut of uninfected neonatal babies, that transmission between babies within NICUs was likely.

Read more →

Graphene oxide reduces the toxicity of Alzheimer's proteins

A probable early driver of Alzheimer’s disease is the accumulation of molecules called amyloid peptides. These cause cell death, and are commonly found in the brains of Alzheimer’s patients. Researchers at Chalmers University of Technology, Sweden, have now shown that yeast cells that accumulate these misfolded amyloid peptides can recover after being treated with graphene oxide nanoflakes.
Alzheimer’s disease is an incurable brain disease, leading to dementia and death, that causes suffering for both the patients and their families. It is estimated that over 40 million people worldwide are living with the disease or a related form of dementia. According to Alzheimer’s News Today, the estimated global cost of these diseases is one percent of the global gross domestic product.
Misfolded amyloid-beta peptides, Aβ peptides, that accumulate and aggregate in the brain, are believed to be the underlying cause of Alzheimer’s disease. They trigger a series of harmful processes in the neurons (brain cells) — causing the loss of many vital cell functions or cell death, and thus a loss of brain function in the affected area. To date, there are no effective strategies to treat amyloid accumulation in the brain.
Researchers at Chalmers University of Technology have now shown that treatment with graphene oxide leads to reduced levels of aggregated amyloid peptides in a yeast cell model.
“This effect of graphene oxide has recently also been shown by other researchers, but not in yeast cells,” says Xin Chen, Researcher in Systems Biology at Chalmers and first author of the study. “Our study also explains the mechanism behind the effect. Graphene oxide affects the metabolism of the cells, in a way that increases their resistance to misfolded proteins and oxidative stress. This has not been previously reported.”
Investigating the mechanisms using baker’s yeast affected by Alzheimer’s disease
In Alzheimer’s disease, the amyloid aggregates exert their neurotoxic effects by causing various cellular metabolic disorders, such as stress in the endoplasmic reticulum — a major part of the cell, in which many of its proteins are produced. This can reduce cells’ ability to handle misfolded proteins, and consequently increase the accumulation of these proteins.

Read more →

Kaiser Permanente Health Care Workers Go on Strike

The health system failed to reach a new contract agreement with some of its unionized employees, who have planned a three-day job action in Kaiser’s facilities in several states.More than 75,000 Kaiser Permanente health care workers began a three-day strike Wednesday morning, after they failed to reach a new contract deal.The walkout started with employees in Virginia and the District of Columbia, where they set up picket lines outside Kaiser’s facilities. A majority of Kaiser’s workers are in California, where many of its unionized employees and those in Colorado, Oregon and Washington are poised to strike at 6 a.m. local time.The union members include support staff and other workers, including X-ray and lab technicians, sanitation workers who disinfect rooms between patients and pharmacy workers who help dispense medications. These workers attend surgeries, run imaging equipment and assist in outpatient clinics. Doctors and many nurses were not part of the labor dispute.The previous contract expired on Saturday. Kaiser, a large nonprofit health system, provides care for 13 million people in eight states. Union leaders say this could be the largest strike by health care workers in recent U.S. history.“Tens of thousands of frontline Kaiser health care workers across the country are ready for an unfair labor practice strike at 6 a.m. today,” the Coalition of Kaiser Permanente Unions, the collection of a dozen unions representing the workers, said in an earlier statement. “Patients and workers need dramatic action now to solve the Kaiser short staffing crisis and to ensure our patients’ safety.”Kaiser said it had “robust contingency plans in place to ensure members continue to receive safe, high-quality care should a strike occur,” emphasizing that all hospitals and emergency departments would remain open.But patients could experience delays in getting appointments, or procedures that are not considered urgent could be postponed.Talks appear to be continuing. Earlier on Wednesday, Kaiser issued a statement that the two sides “are still at the bargaining table, having worked through the night in an effort to reach an agreement.”“There has been a lot of progress,” it continued, “with agreements reached on several specific proposals late Tuesday.” The strains of an acute staffing shortage led to tensions between the unions and Kaiser executives in the run-up to the contract’s expiration. Workers said the lack of adequate staffing at Kaiser facilities created unsafe conditions for patients. The unions argued that Kaiser needed to offer better wages to attract workers and hire enough people to make up for the exodus of staff during the pandemic.In proposals considered for a new four-year contract, the union had sought a $25 hourly minimum wage and increases of 7 percent in the first two years and 6.25 percent in the two years after, according to a recent proposal.Kaiser had countered with minimum hourly wages of between $21 and $23 next year, increasing by a dollar a year. Raises would vary among locations. “It’s so disappointing to see them falling down here,” said Caroline Lucas, the executive director of the Coalition of Kaiser Permanente Unions, which represents about half of Kaiser’s unionized work force.While the pandemic caused an immediate crisis in which workers were stretched too thin, Ms. Lucas said employees had been concerned about short staffing even before Covid hit. “For years, there has been a crisis on the horizon,” she said.Michelle Gaskill-Hames, regional president for Kaiser Permanente in Southern California and Hawaii, had said earlier that Kaiser was dealing with the same staffing problems as other health systems across the country. The group has fared better than many of its competitors, she said, in limiting turnover and hiring replacement staff. “We have really ramped up on aggressive retention and recruitment strategies,” she said.The frustrations of health care workers, who feel they are being forced to care for too many patients for too little pay, have been boiling over across the country. Many of the workers who remain feel burned out and are struggling to handle a higher volume of patients. The concern over inadequate staffing resulted in a nurses’ strike in New York City in January, and there were more than a dozen similar strikes this year in California, Illinois, Michigan and elsewhere.The tight labor market has emboldened many unionized workers, leading to the recently averted strike at United Parcel Service and current picket lines among autoworkers. “Unions are flexing their muscles in a bunch of industries,” said Ruth Milkman, a professor of sociology and labor studies at the City University of New York.The pervasive short staffing in health care gives workers significant leverage to demand better working conditions and higher pay, she said.Many nurses are represented by other unions, including the California Nurses Association, which agreed to a new contract in Northern California last December.The high levels of burnout have exacerbated the staffing shortages, said Ethan Ruskin, a health educator at Kaiser Permanente in San Jose, Calif. Patients have to wait longer than usual for appointments, he said, only to face more delays in the waiting rooms.“If they see something on your mammogram and send you for a sonogram, you’re going to be waiting weeks for a scan,” Mr. Ruskin said. “Meanwhile our sonographers have huge injury rates — things like stress fractures — because they are expected to see twice as many patients as they should.”

Read more →

The Mystery of My Burning Esophagus

My year of torment began with a brutal headache. The pain came on gradually over several weeks, as if some part of my brain were being slowly squeezed in a vise. Darkness lapped at the edge of my vision. Over-the-counter painkillers didn’t help. Occasionally, a dementia-like loss of vocabulary struck, often when I was talking to people over the phone. I found myself unable to recall easy things like “Washington, D.C.” or “George Clooney.” I’d end up staring at my computer without any inkling of what I’d sat down to do.Listen to This ArticleListen to this story in the New York Times Audio app on iOS.I suspected something was wrong with my sinuses because I had sinus infections in the past, and this headache was accompanied by a waterfall of mucus running down the back of my throat: postnasal drip, in medical parlance. I figured it wasn’t Covid, which a test eventually confirmed. When I went to the only ear, nose and throat doctor who could fit me into her schedule, she gently inserted a long, flexible rubber scope into my nose to examine my sinuses. As I sneezed and gagged, she pushed the scope farther, to peer down my throat. I might have reflux, she said — acid splashing up from my stomach into my esophagus. She could see “damage” in my pharynx. She seemed unconcerned, though. Some people have terrible reflux but don’t feel a thing, she said; others have a little reflux, and it causes intense discomfort. I must belong to the former group, if my throat looked like this and I wasn’t feeling pain there now. She prescribed a course of antibiotics to clear out whatever nasty microbes might have established themselves in my sinuses, the presumed source of my pain.Unfortunately, something was starting to disturb my insides. It began as a faint sensation of heat under my sternum and over several weeks grew stronger, until it felt as if some part of me had caught fire. The sensation reached an apogee one night following a meal of greasy quesadillas with hot peppers. After that, I changed my diet, abandoned coffee and avoided heavy foods, all said to aggravate reflux. But whatever was happening to me only got worse. Warmth began to rise in my throat soon after every meal, no matter how light or bland the food. To avoid the feeling of lava bubbling up within me, I ate as little as possible. I started to lose weight.I didn’t know it at the time, but I was embarking on a journey into territory I knew well. My ailment, it would turn out, was of a piece with a much larger development in affluent countries over the past 150 years or so. As improved sanitation, vaccines, antibiotics and other innovations beat back infectious diseases, some chronic diseases have been on the rise, including disorders in which the very immune system meant to protect us turns on us instead. A leading explanation for such self-sabotage involves the changes we have wrought on our microbiomes, the communities of microbes living in and on our bodies. As a science writer, I’d covered this phenomenon extensively. But despite having written a book about some of the diseases involved and the reasons for their increasing prevalence, I hadn’t ever considered how they could lead to the kind of unremitting pain that was making my life so miserable now at 47.I had to call several gastroenterology clinics to find a doctor who could perform an endoscopy reasonably soon. The procedure, which often involves sedation so that a thin tube with a tiny camera at the end can be pushed down the throat, revealed that my esophagus had abnormal rings — swellings — over its entire length, like a corrugated drainpipe. The doctor, my first gastroenterologist, said he couldn’t be certain, but those rings seemed to indicate a rare allergic condition called eosinophilic esophagitis (EoE).Eosinophils are specialized white blood cells that help repel intestinal parasites and bacteria. They can also play a role in various allergic diseases, including asthma and eczema. In my case, though biopsies showed elevated eosinophil numbers, they were below the cutoff used to diagnose EoE. But there was a confounding factor: To treat my presumed reflux, a week earlier I started taking Prilosec, an over-the-counter antacid drug that can also suppress eosinophils. It was impossible, in other words, to say whether I had an allergic condition obscured by the medication, or simply an unusual case of gastroesophageal reflux disease, or GERD.But a definitive diagnosis didn’t really matter, the doctor explained, because EoE and severe reflux are both treated with Prilosec or other drugs in the same class called proton pump inhibitors, or P.P.I.s. These medications suppress the production of the stomach acid that helps digest food. He recommended that I quadruple the dosage.Most people take the drug without problems — P.P.I.s are widely used — but for me the side effects of such a high dose were horrendous. I couldn’t see straight or read very well. I couldn’t concentrate. Worst of all was a bone-crushing fatigue. Getting up from the couch became a groan-inducing ordeal of unsteadiness. My doctor said I’d have to be on this medicine for at least eight weeks. If everything was better, why did I still feel so miserable?Unable to work, I ended up spending the better part of two months lying in the hammock in my tiny backyard. I could no longer tolerate food with strong flavors, so I subsisted on brown rice, lentils, steamed vegetables and small amounts of chicken breast. At some point, my wedding band slipped off my thinning fingers, lost without my realizing it. One evening, my 10-year-old daughter, the eldest of my three children, burst into tears and said, “I just want you to get better!” But my condition worsened. Increasingly I felt as if I couldn’t breathe. I had severe asthma as a child, but the disease hadn’t troubled me greatly since then. Now, however, my breathing became more labored. The usual inhalers didn’t help. The bottom half of my lungs seemed to be filled with cement. And then, starting one morning in July 2021, the gasping attacks began. Every other day or so, an acute feeling of suffocation overwhelmed me. These attacks left me hot, panicked and sweaty. The fastest way to quell them, I discovered, was to sit in front of an air-conditioning unit going full blast and hold my breath for as long as I could. Somehow that calmed what I began to suspect was a problem with my nervous system.I live in the San Francisco Bay Area, and by now I had a new gastroenterologist, a doctor at Stanford Health Care, affiliated with the university and a specialist in EoE. The burning sensation had me convinced that I suffered from severe reflux. But she told me that all the acid-suppressing medicine I was taking — she’d advised me to add a few other types to the mix — meant my stomach probably wasn’t making much acid at all; acid in my esophagus was not causing the pain, most likely. Even so, she ordered tests to confirm her thinking. A pill-shaped gizmo inserted into my lower esophagus was used to measure acidity; another tube of sensors measured how well the sphincter that separated the stomach from the esophagus, which was essential in preventing stomach acid from splashing backward, squeezed shut. The results of these and other exams were both reassuring and baffling: Everything appeared to be working normally. The pressure of my lower esophageal sphincter was fine; the wavelike motion of swallowing, called peristalsis, was normal. There was no acid reflux. The ringlike swellings in my esophagus had faded. The number of allergic eosinophil cells had declined. I faced a conundrum: If everything was better, why did I still feel so miserable?During my years of interviewing doctors, I haven’t been able to help noticing the exasperation some of them feel toward patients who look for medical guidance online — what one of those physicians once called Dr. Google — and then come into the office making demands based on what is often incomplete information or outright misinformation. I tried to walk a fine line with my doctors, pointing out that I was a science writer (blank stares), and that I read a lot of scientific articles (more blank stares, now tinged with apparent dread). I wanted them to know they were the bosses. I just had lots of questions. Convinced that I had an extreme case of GERD, I compiled a list of surgeries and procedures used to tighten or repair the lower esophageal sphincter. I contacted specialists in the breathing problems associated with GERD. I looked into alternative treatments: the sleep aid melatonin; acupuncture; a new acid-suppressing drug first introduced in Japan. My research helped in some areas. It was because of what I had learned about EoE that I left my first gastroenterologist, who didn’t seem to know much about the condition.Yet the endless quest for answers also spiraled into a kind of madness. An ever-expanding decision tree paralyzed me. If it was X, then I’d do Y surgery. If it was A, then I’d take B drug. I was driving myself nuts with all that reading, my wife said. But if I didn’t do this research, I countered, who would? My new gastroenterologist had a theory to explain the all-consuming pain under my sternum. Sometimes patients develop a hypersensitivity syndrome, she told me. The original insult — in my case, inflammation of some kind — might be long gone, but the nerves that convey pain can become overactive and begin firing at the slightest provocation. When this happens, stimuli you normally wouldn’t even notice can cause extreme pain. I was skeptical. The pain felt exactly as if my esophagus were being burned by, yes, hydrochloric stomach acid. How could it be some kind of sensory hallucination?She explained it as “a headache of the esophagus.” And that “headache” might be treatable with an unlikely approach: neuromodulating drugs that were first developed to manage depression. Scientists don’t completely understand how antidepressants help pain syndromes, but certain ones seem to impede pain signals in the nervous system. There were two kinds on offer, she informed me: one that might give me diarrhea but also energy, or another that could make me tired and constipated.No contest: I requested diarrhea with energy. The drug, an antidepressant called duloxetine — one of its brand names is Cymbalta — increases in the brain levels of both serotonin and norepinephrine, chemical messengers that can help modulate pain signals. I didn’t get energy or diarrhea from the duloxetine, however. Instead, I became dizzy and nauseated. Food tasted off. Anything with a soft texture triggered a sense of revulsion. After a few weeks, those side effects faded. And that’s when things began to turn around. I could tolerate more and different kinds of food. Cheese and eggs. A tart apple. One day, after several weeks of feeling better, I ate so much that the burning pain came roaring back. My doctor recommended that I double my duloxetine dose. The improvements accelerated.After six months on the P.P.I.s that made me feel half dead, my gastroenterologist granted my wish to stop taking them. In early 2022, another endoscopy and another acidity study finally, almost a year after the ordeal began, yielded a conclusive diagnosis. Once I was off the P.P.I.s, the corrugated drainpipe-like swellings returned, just without the pain, thanks to the duloxetine. My eosinophil counts, detected in little plugs of flesh the doctor took from my esophageal lining, had skyrocketed. I had eosinophilic esophagitis. My food pipe had been chronically inflamed by an allergic reaction, most likely in response to some food I was eating.As many as one in every 1,000 Americans, according to recent studies, is afflicted with eosinophilic esophagitis, making it rare but not vanishingly so. Although the condition is somewhat obscure, I learned about it years earlier, while researching my 2012 book “An Epidemic of Absence,” which explores the reasons behind the rise of allergic and autoimmune diseases in affluent societies. I had seen it mentioned as one more example of the growing number and variety of allergic diseases we seem prone to developing. I was also, I knew by now, very likely predisposed to develop EoE: male, asthmatic and already allergic to two foods that I knew of (peanuts and sesame make me vomit), all conditions that occur more frequently in people with EoE than those without. In a way, the discovery that I had EoE felt like a diagnosis preordained, like a biological fate.The bigger issue, the one that inspired my book, was the question of where diseases like this came from. Hay fever, one of the most common allergic diseases, seemed to become more prevalent in the late 19th century, as did asthma in the mid-to-late 20th century. But EoE was first understood as a type of food allergy only in the 1990s, after which diagnoses began to increase. While this change probably stemmed in part from doctors’ greater awareness of the disease, research led by Evan S. Dellon, a gastroenterologist who specializes in EoE at the University of North Carolina School of Medicine, suggests that the disease has in fact become more common. When he and his colleagues analyzed Danish records of biopsies taken between 1997 and 2012, they did indeed find that the rate of biopsies — a signal of how often doctors were looking for EoE — doubled. Yet test results and symptoms indicative of EoE rose nineteenfold, far outpacing the jump in biopsies. More recent studies have reached a similar conclusion. When the incidence of a noninfectious disease changes so quickly — faster than our genomes can possibly accumulate new mutations that increase susceptibility — scientists suspect that changes in the environment are responsible. And studies involving twins point to an environmental trigger for EoE. According to one paper on both identical and fraternal twins, just 14.5 percent of the risk was attributable to genetics, with the rest determined by the twins’ surroundings. “We think it’s something in the prenatal environment,” says Amanda Muir, a pediatric gastroenterologist at the Children’s Hospital of Philadelphia, referring to in utero exposures.Other possible factors include common chemicals, like pesticides and food additives. For one Mayo Clinic study published earlier this year, scientists induced eosinophilic inflammation in the esophagi of mice merely by giving them drinking water with a small amount of detergent in it. The soap used in the study, sodium dodecyl sulfate, is an ingredient in some toothpastes and dish soaps. None of these possible explanations for EoE are mutually exclusive. Its causes are most likely multifactorial, Dellon says, with several simultaneous “hits,” as he calls them, required to induce the disease. Changes to the microbiome, which can occur for all sorts of reasons, also seem to be a major factor making people susceptible to EoE. Elizabeth Jensen, an associate professor of epidemiology at Wake Forest University School of Medicine, and her colleagues have found that having been breastfed — which, along with its other benefits, is thought to cultivate a healthier microbial garden in the infant gut — is protective against the disease, for example, but so far only in children with certain gene variants suspected of making the esophageal barrier more permeable. Jensen, who suffers from EoE herself, thinks that one explanation for this finding is that by nudging children’s microbiomes in a healthier direction, breastfeeding blunts their chances of developing EoE.Conversely, antibiotics taken early in life are associated with an increased risk of EoE later, according to Jensen’s research (a pattern also observed in studies of those with asthma, pediatric-onset inflammatory bowel disease and pediatric autoimmune arthritis). That’s probably for exactly the opposite reason: Along with the targeted pathogen, the medicine can kill off protective microbes. On the whole, Jensen’s findings suggest that it may not be some new environmental exposure alone that is driving the rise of EoE but also that we are peeling away layers of protection — and in some cases may never acquire that protection at all — by having changed what microbes live around, in and on our bodies.Here, Jensen’s research intersects with a much larger body of science that is sometimes misleadingly labeled the “hygiene hypothesis,” though it has nothing to do with personal hygiene. The research posits that the rise of allergic diseases over the past 150 years, and the apparent increase in many autoimmune disorders as well, may be evidence of a single phenomenon: a population-wide derangement of our microbial communities and the immune systems these communities train — a single problem, but one that expresses itself in many different ways. By late autumn in 2021, nine months into my ailment, I faced a new difficulty. The duloxetine never delivered on the promised energy (or diarrhea). But it did cause drenching night sweats and sleepiness. I was constantly yawning. And somewhere along the way, I lost all drive to do much of anything. The antidepressant was, I surmised, depressing me. I had to continue taking it, I knew, to keep the horrible pain at bay, but I yearned for an “upper,” some kind of stimulant. I asked my doctors to prescribe a drug that would animate me — Ritalin, perhaps. They were hesitant to prescribe a habit-forming medicine to counter the side effects of another drug and recommended evaluation by a psychiatrist instead. After much searching — the surge in mental-health troubles during the pandemic was keeping psychiatrists booked up — I found one who could see me over Zoom. He prescribed a drug called bupropion, which affects the dopamine pathways in the brain that underlie our sense of motivation and reward. (It’s also used to help people stop smoking.) Bupropion can cause dry mouth and insomnia, but I didn’t develop these side effects, thankfully, and the medicine ended up being miraculous. Very quickly, I could focus again. I cared about things. When I told my sister about this pill, she said, half-jokingly, “Can I have that psychiatrist’s number?”I saw disparate-seeming episodes that had distressed me going back decades in a new light.There were no F.D.A.-approved treatments for EoE itself. The available treatments were off-label, consisting of drugs primarily prescribed for other conditions. I hadn’t tolerated the high doses of P.P.I.s, the usual first treatment, so in February 2022, I began swallowing liquid steroids meant to be inhaled as an asthma treatment; I mixed the medicine with honey to help it stick to my esophageal wall. According to biopsies taken soon after, from the fourth endoscopy within a year’s time, the medicine did a good job of controlling the allergic inflammation.Steroids can cause cataracts, osteoporosis and other complications if used in excess or for too long. But the type I’ve been taking for over a year and a half, called budesonide, is formulated to be topical; supposedly only a minimal amount enters circulation. Eventually I hope to identify the food I’m allergic to so I can avoid it and stop the steroids completely. But because skin-prick tests and blood tests, the usual ways of identifying an allergy, do not work well for EoE — neither test really measures what eosinophils are specifically doing in your esophagus, the location of this disorder — the only reliable way to identify an allergen is to eliminate certain food groups and then examine the esophagus directly to see if the inflammation has improved, followed by additional endoscopies as you reintroduce each food group. The onerous process can require many months to complete, and depending on what foods turn out to trigger an allergy, they can be hard to avoid anyway. So my gastroenterologist and I decided that for the time being, I would continue treating the EoE with steroids.In May 2022, the F.D.A. approved the first drug for EoE. Called Dupixent, it inhibits two immune-signaling proteins that help drive the type of allergic inflammation underlying EoE. I was raring to get on the stuff; I’d been reading about it in journal articles and on medical news sites for months. But after learning about its potential downsides — including the activation of herpes virus infections, a rash, eye inflammation and the possibility that it might not be covered by insurance — I held off. With any new drug, my doctor pointed out, “you don’t want to be first. You want to be next.” Now that I knew what ailed me, and had a treatment regimen that was at least controlling the problem, I saw disparate-seeming episodes that had distressed me going back decades in a new light: a painful lump in my throat in my 20s that I attributed to stress; an occasional sensation of breathlessness, also in my 20s, that I thought was allergies. All along, some still unidentified food was probably inflaming my esophagus. The long lag time between the appearance of symptoms and a diagnosis wasn’t unusual, I learned. Evan Dellon of U.N.C.’s medical school told me that the lag time for diagnosing this condition typically ranges between five and eight years. People with EoE often have difficulty swallowing food years before they know what the cause is. They may develop unconscious coping mechanisms, reflexively avoiding mealy potatoes, say, or gristly steak. I had developed my own workarounds. After choking on a Tylenol pill years ago, for example, I started crushing all pills before swallowing them so they wouldn’t stick. Perhaps because of the constant fear of choking, esophagitis is closely linked with anxiety and depression. More than a quarter of adults with EoE take anti-anxiety or antidepressant drugs — a “really striking finding,” Dellon says. Food, he says, should never catch in your esophagus, a long flexible and muscular tube that extends down from the throat and that, when healthy, should be stretchy and well lubricated enough to pass large blobs of chewed-up stuff. “Nothing is normal about food sticking,” he says. The burning pain I felt wasn’t unusual, either, Dellon told me. He pointed to animal experiments that showed how an allergy could, over time, lead to a pain syndrome. Scientists induced EoE in guinea pigs and let it progress for a while. The chronic allergic inflammation in their esophagi eventually heightened the sensitivity of nearby nerve cells to painful stimuli. In Dellon’s experience with people, that sort of hypersensitivity can persist long after the inflammation has resolved. “That’s what I see relatively commonly in patients,” he said. Everything looks normal. No swelling. Biopsies show a reduction in eosinophils. But the patients complain of persistent pain. Doctors are increasingly aware of these kinds of pain syndromes in many disorders, including GERD. The condition, whose primary symptom is known colloquially as heartburn, is pervasive, afflicting an estimated one in five Americans. Some of these patients continue to feel intense pain even after their stomach acid has been reduced with antacids, a malady most likely caused by a hypersensitivity syndrome similar to mine. Ronnie Fass, the medical director of the Digestive Health Center at MetroHealth in Cleveland, argues that the treatment of GERD-like symptoms should accommodate this new understanding: Neuromodulators should be considered right away for those experiencing esophageal pain. “We should not wait until patients fail treatment to identify that esophageal hypersensitivity plays an important role,” he told me. Unfortunately, he adds, patients often refuse antidepressants because in their minds, using psychiatric medicine means they’re mentally ill. They tend to request opiates instead.As for the air hunger I experienced, my gastroenterologist rejected any connection to my esophageal problems. I’d sent her articles on how reflux disease could worsen asthma, trying to convince her that the two could be linked. Because the megadose of P.P.I.s I was taking at the time meant my stomach probably hadn’t been producing enough acid to irritate my esophagus, my breathing difficulties more likely stemmed from an allergic reaction to something in the environment, she said, because I was clearly an allergy-prone fellow. I didn’t press her on this, but I didn’t completely agree with that reasoning. To my mind, it didn’t matter whether irritation was actually occurring. What mattered was whether my nervous system thought it was. That had been the great lesson of my pain syndrome: The burning sensation persisted even when the disease that caused it had quieted down.Indeed, the breathing problems began to improve only once I started the duloxetine, suggesting (to me, at any rate) that the issues with my lungs, like the pain syndrome, emanated from a nervous system at cross purposes with itself. Yet when I began asking experts how these things might be related, several of them noted that reflux could exacerbate asthma or cause a sensation of breathlessness, but there wasn’t enough data to say the same about EoE. When I brought up my episodes of feeling suffocated, the scientists waffled. I got the sense that they thought I was really having panic attacks. It wasn’t until I called Brendan Canning, a professor of medicine at Johns Hopkins, that I found someone willing to speculate how an allergy in the esophagus might lead to the terrifying sensation of drowning. Canning, a self-described “science nerd,” is not a physician but a researcher who focuses on allergies and airways. He explained to me that the nerves that transmit pain, air hunger and other information from our organs lead, like telegraph lines, to very primitive parts of the brain that are physically near one another. Because of this proximity, the neurons receiving signals sometimes have a hard time determining precisely where the message is coming from. It might be that any irritation in the esophagus, whether from an upward surge of acid or inflammation spurred by a food allergy, could be interpreted as originating in the lungs — or even the heart — and a body might respond, as mine apparently did, with the panic of someone who’s drowning. “It’s not surprising that this could happen,” Canning said, given “the tremendous overlap that exists in the brain stem.” Why has there been no moonshot program to conquer allergic disease? Eosinophilic esophagitis is rare, but allergic diseases as a group include the itchy skin of eczema, the hives and vomiting of food allergies, the runny noses of hay-fever season, the breathing problems of allergic asthma and more. They afflict nearly one in three Americans, making life miserable for vast swaths of the population. And if the microbiome has been implicated for so long in these ailments — and now in EoE — why is it taking so long for a microbiome-targeting therapy to become available? “We’re wondering about that, too,” Alkis Togias, the chief of the Allergy, Asthma and Airway Biology Branch at the National Institute of Allergy and Infectious Diseases, told me. In recent years, the institute has fielded only a few applications for microbiome-related studies, he says — far fewer than anticipated. Scientists aren’t convinced that they have identified the right microbes, he suspects. But Togias says that the agency is taking the allergy problem seriously and that funding for the study of food allergies, for example, has risen to between $60 million and $80 million per year now from $1.3 million in 2003. “It’s a very big jump,” he says. “But I totally agree with you. It should be more.” Much of the science on the microbiome suggests that what you encounter early in life sets the tone for how your immune system works later, so many in the field understandably focus on prevention, rather than on how to correct an already-dysfunctional community of microbes. But a few researchers have been pursuing the prospect of changing those adult microbiomes as well. A few years ago, Rima Rachid, the director of the Allergen Immunotherapy Program at Boston Children’s Hospital, and her colleagues gave 10 adult volunteers with peanut allergies microbes from nonallergic donors. The subjects ingested, in capsule form, carefully screened feces from healthy people in order to see if the microbes it contained could give them relief from nut allergies. After four months, three subjects could tolerate at least three times the amount of peanut protein compared with amounts that originally triggered reaction. That translated to a little more than one peanut. Three out of five other patients who, before swallowing the capsules, took antibiotics, presumably clearing out their own distorted microbiomes and making it easier for the new ones to establish themselves, could tolerate more than two peanuts’ worth of protein. The study was tiny, lacked a control group and was hardly conclusive. (A follow-up study is underway with children.) And EoE doesn’t work exactly like these more common nut allergies. But the research gives people like me, adults with established allergic disease, reason to hope. “I don’t think you can say that once your microbiome is formed, you’ve lost hope,” Rachid told me. “There is a possibility of changing the microbiome.”There may also be a new class of microbe-inspired medicine on the horizon, a drug that doesn’t even have a name, just a number: ‘1104. Early studies suggest it reduces eosinophils in patients with EoE, as well as other white blood cells that contribute to the disease. It also increases patients’ own “regulatory” T cells and B cells, which are thought to be crucial in preventing the inappropriate immune aggression that underlies many allergic diseases. The drug is based on a molecule derived from Mycobacterium tuberculosis, the pathogen that causes tuberculosis. The bacterium can establish long-term infection in the body by suppressing the immune system. Some studies have observed that people carrying latent TB infections appear to have a lower risk of developing asthma, as do those who have been vaccinated against TB. Revolo Biotherapeutics, the company developing ‘1104, is seeking to leverage the bacterium’s ability to “reset” the immune system. If further human trials pan out, maybe we’re headed toward a new generation of drugs derived from our interactions with microbes that inhabit our bodies.In June 2022, I decided I’d had enough of duloxetine. It proved pivotal to my recovery, but after 10 months of constant exhaustion — I’d stopped the bupropion, which turned out to irritate my esophagus — I was ready to be weaned off it. My psychiatrist warned me about possible withdrawal symptoms, including “zapping” sensations akin to electric shocks. The warning didn’t quite prepare me. The “electric” shocks were more like being struck unconscious for a millisecond while cold, blue flames rushed up my backbone.For about a week, the side effects were intense enough that I considered resuming the duloxetine. (As it happens, Eli Lilly, the company that first manufactured duloxetine, has been repeatedly sued by patients claiming that it hadn’t given them full warning about the difficulty of discontinuing the antidepressant.) Happily though, the worst of the symptoms began to fade after about two weeks. And I no longer felt as if I was constantly fighting the urge to nap, which was encouraging. My mind felt less enveloped in cobwebs. And the burning pain remained quiescent. I was not cured, just much better. I occasionally felt nagging pain under my sternum. I still couldn’t eat certain foods, particularly the spicy cuisine I used to adore, and the heavy, greasy foods loved by many. My breathing still felt off sometimes, as if I couldn’t fully inhale. But there were periodic moments when I felt better than I had in a long time, presumably because I was finally treating a disease that had been on a slow burn for years, maybe decades.And then this past February, about seven months after my last dose of duloxetine, the burning returned. The paradox was that even though I was now treating the EoE with steroids, I felt pain as if the disease were raging uncontrolled. Evidently my nervous system could be easily reactivated to produce this burning sensation. I went back on the duloxetine, although this time a much lower dose did the trick.I often remind myself how fortunate I’ve been. Because of my work as a science writer, I already had some familiarity with EoE and I was relatively comfortable navigating the byzantine medical system and advocating for myself. My wife has a well-paying job that allowed me to stop working for a year and not worry too much about finances or health insurance. New treatments are either available or in development for a disorder doctors barely understood just three decades ago. Still, any disease in which the body overreacts (allergy) or turns against itself (autoimmunity) is bound to inspire a unique kind of desperation. Those of us in this club we never asked to join have bodies that are, in ways both literal and figurative, self-lacerating. Our magnificent and complicated bodily defenses, our immune systems, instead torment us. What we yearn for is a single treatment that can, once and for all, correct this wayward tendency toward self-destruction.Moises Velasquez-Manoff is a writer based in California. His last article for the magazine was on vaccine hesitancy in the wake of the Covid-19 pandemic. He is also the author of the book “An Epidemic of Absence: A New Way of Understanding Allergies and Autoimmune Diseases.”

Read more →